All Stories

  1. Thermodynamic Determinants in Antibody-Free Nucleic Acid Lateral Flow Assays (AF-NALFA): Lessons from Molecular Detection of Listeria monocytogenes, Mycobacterium leprae and Leishmania amazonensis
  2. Long-term storage stability of PGL-I coated ELISA plates for anti-Mycobacterium leprae IgM detection
  3. Production of antigens expressed in Nicotiana benthamiana plant and Escherichia coli for the SARS-CoV-2 IgG antibody detection by ELISA
  4. An indirect ELISA for detecting anti-SARS-CoV-2 antibodies in human sera using a baculovirus-expressed recombinant nucleocapsid antigen
  5. Development and evaluation of a Lateral flow immunoassay (LFIA) prototype for the detection of IgG anti-SARS-CoV-2 antibodies
  6. Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR)
  7. Direct immunoassay on a polyester microwell plate for colorimetric detection of the spike protein in swab and saliva samples
  8. Challenges and advances in serological and molecular tests to aid leprosy diagnosis
  9. A novel highly specific biotinylated MAC-ELISA for detection of anti-SARS-CoV-2 nucleocapsid antigen IgM antibodies during the acute phase of COVID-19
  10. Detection of Listeria monocytogenes using an immunochromatographic point of care test based on anti-internalin A and B antibodies and a nano-biotinylated detection complex
  11. Prediction of the occurrence of leprosy reactions based on Bayesian networks
  12. Practical use of tobravirus-based vector to produce SARS-CoV-2 antigens in plants
  13. Combined antibodies against internalins A and B proteins have potential application in immunoassay for detection of Listeria monocytogenes
  14. Antibody- and nucleic acid–based lateral flow immunoassay for Listeria monocytogenes detection
  15. A social network approach for the study of leprosy transmission beyond the household
  16. Listeria monocytogenes: review of pathogenesis and virulence determinants-targeted immunological assays
  17. Soropositividade ao PGL-I em um centro de reintegração para pessoas atingidas pela hanseníase e diferentes Regiões do Município de Anápolis-Goiás / Seropositivity to PGL-I in a reintegration center for people affected by leprosy and different regions i...
  18. Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay
  19. Human Genetic Susceptibility of Leprosy Recurrence
  20. Reply of the authors of the Continuing Medical Education article to Dr. Jaison Barreto and Dr. Laila Laguiche
  21. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach
  22. Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT
  23. Development of a nanogold slot blot inhibition assay for the detection of antibodies against bovine herpesvirus type 1
  24. Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae
  25. Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients
  26. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients
  27. Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases
  28. Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR)
  29. Fatores associados à coinfecção tuberculose e HIV: o que apontam os dados de notificação do Estado do Amazonas, Brasil, 2001-2012
  30. Could Mycobacterium leprae Infection Be an Occupational Disease? A Survey in Healthcare Workers From an Endemic Area in the Amazonian Region
  31. Description of Leprosy Classification at Baseline Among Patients Enrolled at the Uniform Multidrug Therapy Clinical Trial for Leprosy Patients in Brazil
  32. Temporal distribution of tuberculosis in the State of Amazonas, Brazil
  33. Multidrug-resistant tuberculosis in the Amazonas State, Brazil, 2000–2011
  34. Evaluation of a rapid serological test for leprosy classification using human serum albumin as the antigen carrier
  35. Tuberculosis Infection Control: Potential Benefit of a New Rapid Tuberculosis Test in a Human Immunodeficiency Virus/AIDS Reference Hospital
  36. Phage Display and Synthetic Peptides as Promising Biotechnological Tools for the Serological Diagnosis of Leprosy
  37. Mycobacterium tuberculosis Infection in Young Children: Analyzing the Performance of the Diagnostic Tests
  38. Primary drug resistance among pulmonary treatment-naïve tuberculosis patients in Amazonas State, Brazil
  39. Phenolic Glycolipid-I Does Not Cross-react With Visceral Leishmaniasis Sera in a Brazilian Subset
  40. Serology with ML Flow test in health professionals from three different states of Brazil
  41. Increased Sensitivity in Diagnosis of Tuberculosis in HIV-Positive Patients through the Small-Membrane-Filter Method of Microscopy
  42. Historical analysis of the records of sylvan yellow fever in the State of Amazonas, Brazil, from 1996 to 2009
  43. Evaluation of New Strategies for the Diagnosis of Tuberculosis Among Pediatric Contacts of Tuberculosis Patients
  44. Primary multidrug-resistant tuberculosis and its control implications in the State of Amazonas, Brazil: report of 3 cases
  45. Impact of PGL-I Seropositivity on the Protective Effect of BCG Vaccination among Leprosy Contacts: A Cohort Study
  46. Factors Associated with Tuberculosis Treatment Default in an Endemic Area of the Brazilian Amazon: A Case Control-Study
  47. Correlation between ELISA and ML Flow assays applied to 60 Brazilian patients affected by leprosy
  48. The additional benefit of the ML Flow test to classify leprosy patients
  49. Associação entre reação hansênica após alta e a carga bacilar avaliada utilizando sorologia anti PGL-I e baciloscopia
  50. Associação do teste sorológico ML Flow com a baciloscopia
  51. Avaliação da concordância entre exames clínicos e laboratoriais no diagnóstico da hanseníase
  52. Sorologia rápida para hanseníase (teste ML Flow) em pacientes dimorfos classificados como paucibacilares pelo número de lesões cutâneas: uma ferramenta útil
  53. Sorologia da hanseníase utilizando PGL-I: revisão sistemática
  54. Sorologia PGL-I na hanseníase
  55. Pesquisa de anticorpos anti PGL-I através de ELISA em tatus selvagens do Brasil
  56. Fatores de risco para a soropositividade do ML Flow em pacientes com hanseníase
  57. Soroprevalência do teste ML Flow em contatos de hanseníase de Minas Gerais
  58. A influência do teste sorológico ML Flow na classificação da hanseníase
  59. A relação entre soroprevalência de anticorpos contra o glicolipídeo fenólico-I entre crianças em idade escolar e endemicidade da hanseníase no Brasil
  60. Comportamento dos testes sorológicos ML Flow e ELISA (PGL-I) em áreas endêmica e não endêmica de hanseníase
  61. O uso da sorologia como ferramenta adicional no apoio ao diagnóstico de casos difíceis de hanseníase multibacilar: lições de uma unidade de referência
  62. High prevalence of vasomotor reflex impairment in newly diagnosed leprosy patients
  63. Postgenomic Approach To Identify Novel Mycobacterium leprae Antigens with Potential To Improve Immunodiagnosis of Infection
  64. Simple and Fast Lateral Flow Test for Classification of Leprosy Patients and Identification of Contacts with High Risk of Developing Leprosy
  65. Dipstick assay to identify leprosy patients who have an increased risk of relapse
  66. Simple dipstick assay for semi-quantitative detection of neopterin in sera
  67. The use of whole blood in a dipstick assay for detection of antibodies to Mycobacterium leprae: a field evaluation